Heart Failure 2022: Ghrelin-HF: Intravenous Ghrelin In Patients with HFpEF | Prof Lars Lund

Просмотров: 229   |   Загружено: 2 год.
icon
Radcliffe Cardiology
icon
6
icon
Скачать
iconПодробнее о видео
Watch on Radcliffe Cardiology:

In this short interview from HF 22, Prof Lars Lund (Karolinska Institute, Stockholm, SE) joins us on-site to discuss the outcomes of the Ghrelin-HF study. This was a placebo controlled, randomised trial that evaluated the effects of intravenous ghrelin in patients with heart failure with preserved ejection fraction (HFpEF).

Discussion Points:

-Aims of This Study
-Mechanism of Action
-Patient Cohort and Study Design
-Key Findings
-Take-Home Messages

Recorded on-site at HF, Madrid, 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Похожие видео

Добавлено: 55 год.
Добавил:
  © 2019-2021
  Heart Failure 2022: Ghrelin-HF: Intravenous Ghrelin In Patients with HFpEF | Prof Lars Lund - RusLar.Me